Intravitreal Injection of TIMP3 or the EGFR inhibitor erlotinib offers protection from oxygen-induced retinopathy in mice

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 1, 2013, Pages 864-870

  Hewing, Nina Jasmin ^a,b,c   Weskamp, Gisela ^a   Vermaat, Joost ^d   Farage, Eric ^d   Glomski, Krzysztof ^a,b   Swendeman, Steven ^a   Paul Chan, Robison Vernon ^b   Chiang, Michael F ^e   Khokha, Rama ^f   Anand Apte, Bela ^d   Blobel, Carl Peter ^a,b,d  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MATRIX METALLOPROTEINASE; OXYGEN; TISSUE INHIBITOR OF METALLOPROTEINASE;

AMBIENT AIR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CENTRAL AVASCULAR AREA; CONTROLLED STUDY; EYE PROTECTION; LUNG SMALL CELL CANCER; MOUSE; NEOVASCULAR TUFT; NONHUMAN; PREVENTION STUDY; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RETINA NEOVASCULARIZATION; RETINOPATHY;

ANGIOGENESIS INHIBITORS; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; INTRAVITREAL INJECTIONS; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETINAL DISEASES; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 84874723284     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10954     Document Type: Article

References (41)

1. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007;10:133-140.
2. Bradley J, Ju M, Robinson GS. Combination therapy for the treatment of ocular neovascularization. Angiogenesis. 2007; 10:141-148.
3. Edwards AO, Malek G. Molecular genetics of AMD and current animal models. Angiogenesis. 2007;10:119-132.
4. Sherris D. Ocular drug development-future directions. Angiogenesis. 2007;10:71-76.
5. Weskamp G, Mendelson K, Swendeman S, et al. Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. Circ Res. 2010;106:932-940.
6. Peschon JJ, Slack JL, Reddy P, et al. An essential role for ectodomain shedding in mammalian development. Science. 1998;282:1281-1284.
7. Sahin U, Weskamp G, Zhou HM, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFRligands. J Cell Biol. 2004;164:769-779.
8. Blobel CP. ADAMs: key players in EGFR-signaling, development and disease. Nat Rev Mol Cell Bio. 2005;6:32-43.
9. Mahmoodi M, Sahebjam S, Smookler D, Khokha R, Mort JS. Lack of tissue inhibitor of metalloproteinases-3 results in an enhanced inflammatory response in antigen-induced arthritis. Am J Pathol. 2005;166:1733-1740.
10. Mohammed FF, Smookler DS, Taylor SE, et al. Abnormal TNF activity in Timp3-/- mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet. 2004;36:969-977.
11. Murthy A, Defamie V, Smookler DS, et al. Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice. J Clin Invest. 2010;120: 2731-2744.
12. Smookler DS, Mohammed FF, Kassiri Z, Duncan GS, Mak TW, Khokha R. Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J Immunol. 2006;176: 721-725.
13. Horiuchi K, Le Gall S, Schulte M, et al. Substrate selectivity of EGF-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol Biol Cell. 2007;18: 176-188.
14. Le Gall S, Bobe P, Reiss K, et al. ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as TGFa, L-Selectin and TNFa. Mol Biol Cell. 2009;20:1785-1794.
15. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000;1477:267-283.
16. Kwak HI, Mendoza EA, Bayless KJ. ADAM17 co-purifies with TIMP-3 and modulates endothelial invasion responses in threedimensional collagen matrices. Matrix Biol. 2009;28:470-479.
17. Saunders WB, Bohnsack BL, Faske JB, et al. Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3. J Cell Biol. 2006;175:179-191.
18. Janssen A, Hoellenriegel J, Fogarasi M, et al. Abnormal vessel formation in the choroid of mice lacking tissue inhibitor of metalloprotease-3. Invest Ophthalmol Vis Sci. 2008;49:2812-2822.
19. Ebrahem Q, Qi JH, Sugimoto M, et al. Increased neovascularization in mice lacking tissue inhibitor of metalloproteinases-3. Invest Ophthalmol Vis Sci. 2011;52:6117-6123.
20. Auricchio A, Behling KC, Maguire AM, et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther. 2002;6:490-494.
21. Qi JH, Ebrahem Q, Moore N, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med. 2003;9:407-415.
22. Gridelli C, Maione P, Bareschino MA, et al. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments. Anticancer Res. 2010;30:1301-1310.
23. Leco KJ, Waterhouse P, Sanchez OH, et al. Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J Clin Invest. 2001;108:817-829.
24. Stahl A, Connor KM, Sapieha P, et al. Computer-aided quantification of retinal neovascularization. Angiogenesis. 2009;12:297-301.
25. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995;92:905-909.
26. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35: 101-111.
27. Connor KM, Krah NM, Dennison RJ, et al. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc. 2009;4:1565-1573.
28. Remtulla S, Hallett PE. A schematic eye for the mouse, and comparisons with the rat. Vision Res. 1985;25:21-31.
29. Maretzky T, Evers A, Zhou W, et al. Migration of growth factorstimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17. Nat Commun. 2011;2:229.
30. Swendeman S, Mendelson K, Weskamp G, et al. VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling. Circ Res. 2008;103:916-918.
31. Guaiquil VH, Swendeman S, Zhou W, et al. ADAM8 is a negative regulator of retinal neovascularization and of the growth of heterotopically injected tumor cells in mice. J Mol Med. 2010;88:497-505.
32. Zeng Y, Rosborough RC, Li Y, Gupta AR, Bennett J. Temporal and spatial regulation of gene expression mediated by the promoter for the human tissue inhibitor of metalloproteinases-3 (TIMP-3)-encoding gene. Dev Dyn. 1998;211:228-237.
33. Jomary C, Neal MJ, Jones SE. Increased expression of retinal TIMP3 mRNA in simplex retinitis pigmentosa is localized to photoreceptor-retaining regions. J Neurochem. 1995;64: 2370-2373.
34. Sato T, Kusaka S, Hashida N, Saishin Y, Fujikado T, Tano Y. Comprehensive gene-expression profile in murine oxygeninduced retinopathy. Br J Ophthalmol. 2009;93:96-103.
35. Franzke CW, Cobzaru C, Triantafyllopoulou A, et al. Epidermal ADAM17 maintains the skin barrier by regulating EGFR liganddependent terminal keratinocyte differentiation. J Exp Med. 2012;209:1105-1119.
36. Jackson LF, Qiu TH, Sunnarborg SW, et al. Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. Embo J. 2003;22:2704-2716.
37. Sternlicht MD, Sunnarborg SW, Kouros-Mehr H, Yu Y, Lee DC, Werb Z. Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. Development. 2005;132:3923-3933.
38. Chalaris A, Adam N, Sina C, et al. Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med. 2010;207:1617-1624.
39. Xiang N, Zhao MJ, Li XY, Zheng HH, Li GG, Li B. Redundant mechanisms for vascular growth factors in retinopathy of prematurity in vitro. Ophthalmic Res. 2011;45:92-101.
40. Zhao M, Shi X, Liang J, et al. Expression of pro-and antiangiogenic isoforms of VEGF in the mouse model of oxygeninduced retinopathy. Exp Eye Res. 2011;93:921-926.
41. McColm JR, Geisen P, Hartnett ME. VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. Mol Vis. 2004;10:512-520.